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Pharmaceutics
repeated administrations of high doses to maintain 
effective plasma concentrations, thus reducing patient 
compliance and/or enhancing the incidence of side-effects. 
Side effects and the need for administration, twice or 
thrice a day when larger doses are required, can decrease 
patient compliance. Sustained release (SR) formulation that 
would maintain the plasma levels of the drug for eight to 
twelve hours might be sufficient for once daily dosing of 
metformin. Administration of a sustained-release, once-
a-day metformin dosage form could reduce the dosing 
frequency and improve patient compliance.[2] Sustained or 
controlled drug delivery occurs when embedded within a 
polymer that may be natural or semi-synthetic or synthetic 
in nature. The polymer is judiciously combined with the 
drug or other active ingredients in such a way that the active 
INTRODUCTION
Metformin hydrochloride (MET) is a highly water-soluble 
anti-hyperglycemic agent used in the treatment of type 
2 non-insulin-dependent diabetes mellitus. Its relatively 
low (50 – 60%) bioavailability, together with its short and 
variable biological half-life (1.5 – 4.5 hours),[1] require 
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ABSTRACT
Metformin hydrochloride (MET) sustained-release solid dispersions (SD) were prepared by the solvent 
evaporation and closed melt method, using compritol 888 ATO as the polymer with five different drug-carrier 
ratios. Characterization of solid dispersion was carried out by Fourier Transform Infrared (FTIR) spectroscopy, 
ultraviolet (UV) spectroscopy, Differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD). The FTIR 
and UV studies suggested that no bond formation had occurred between the polymer and the drug. DSC and 
XPRD results ruled out any interaction or complex formation between the drug and the polymer. The formulated 
SD had acceptable physicochemical characters and SD with a 1 : 4 drug : Polymer ratio, which released the drug 
over an extended period of eight-to-ten hours. The data obtained from the in vitro release studies were fitted 
with various kinetic models and were found to follow the Korsmeyer-Peppas equation. The prepared SD showed 
good stability over the studied time period. The solvent evaporation method was found to be more helpful than 
the closed melt method, giving the sustained release action. The SD with a 1 : 4 ratio of drug to polymer, by the 
solvent evaporation method, was selected as the most effective candidate for the subsequent development of 
a well-timed, sustained-release dosage form of the drug.
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agent is released from the material in a predetermined 
fashion and releases the drug at a constant rate for the 
desired time period.[3]
Solid dispersion (SD), in which compounds are dispersed 
into water-soluble carriers, has been generally used to 
improve the dissolution properties and the bioavailability 
of drugs that are poorly soluble in water.[4] Solid dispersion 
has also been applied for the controlled release of drugs. 
Previous reports have shown that by using solid dispersions 
it is possible to precisely control the rate of release of 
an extremely water soluble drug, such as oxprenolol 
hydrochloride[5] and that of phenacetin[6] and diclofenac 
sodium[7] as well. These studies have shown that there is a 
linear relationship between the rate of release.
Polymers that primarily form insoluble or skeleton matrices 
are considered as the first category of retarding materials. 
The second class represents hydrophobic and water 
insoluble materials, which are potentially erodible and the 
third group exhibits hydrophilic properties.[8] The drug 
release for extended duration, particularly for highly water-
soluble drugs, using a hydrophilic matrix system is restricted 
due to the rapid diffusion of the dissolved drug through 
the hydrophilic gel network. For such drugs with high 
water solubility, hydrophobic polymers (waxes) are suitable 
as matrix forming agents for developing sustained-release 
dosage forms. Hydrophobic polymers provide several 
advantages, ranging from good stability at varying pH values 
and moisture levels, to well-established safe applications.[9]
Over the past decade, glyceryl behenate has been used for 
controlled-release applications by direct compression[10] and 
more recently by : Hot-melt coating,[11] melt granulation[12] 
or pelletization.[13] This glyceride mixture is known to 
exhibit a complex polymorphism depending on many 
parameters such as crystallization rate or temperature of 
storage.[12] Compritol 888 ATO consists of a mixture of 
mono-, di- and tribehenates of glycerol (18, 52, and 28% 
in weight, respectively) and presents a drop point ranging 
from 69oC to 74oC and a hydrophilic–lipophilic balance 
value of 2. More recently, this mixture of glycerides has 
been designed to provide sustained release of drugs. 
Such release would not be obtained from more defined 
compounds like pure di – or triglycerides.[14]
Therefore, in the present study, solid dispersions were 
prepared using compritol 888 ATO by different methods, 
that is, physical mixing, closed melt method, and the solvent 
evaporation method, and characterized by differential 
scanning calorimetry (DSC), X-ray powder diffractometry 
(PXRD), and Fourier transform infrared spectroscopy 
(FTIR) in order to carefully investigate and compare the 
physical–chemical properties of the obtained dispersions, 
for a rational selection of the best one. In addition, solid 
dispersions were examined for a drug release pattern and 
release mechanism.
MATERIALS AND METHODS
Materials
Metformin hydrochloride was kindly supplied by Indoco 
Remedies (Goa, India) and glyceryl behenate (Compritol 
888 ATO) were obtained from Colorcon Asia Pvt. Ltd 
(Mumbai, India). All other chemicals and solvents were 
of reagent grade.
Preparation methods
Preparation ol physical mixtures
Physical mixtures (PM)  [15] of MET and compritol in 
powder form were mixed in mortar and passed through 
sieve mesh No. 60. ThePM were prepared in the following 
ratios : MET : Compritol in the ratios of 1 : 1, 1 : 2, 1 : 3, 
1 : 4, and 1 : 5.
Solis dispersions prepared by the solvent evaporation method[16]
Solid dispersions were prepared by dissolving accurately 
weighed amounts of compritol and MET in chloroform. 
After complete dissolution, the solvent was left to evaporate 
in open air for two days. Subsequently, the solid mass 
was ground and passed through sieve No. 60. The sieved 
ground powders were stored at 25°C in a desiccator, in a 
screw-capped glass vial until use.
Solis dispersions prepared by the closed melt method
Solid dispersions were prepared by the closed melting 
method[17] as follows. From the PMs, 2 g were placed into 
each ampule and then sealed. The ampules were then heated 
at 80°C for 10 minutes. Subsequently they were opened and 
dried for 10 minutes at each heating temperature, in order 
to remove the water. The samples were collected from the 
ampules and kept overnight, triturated, and passed through 
a 60 No. sieve. The solid dispersions were then stored in 
air tight containers until evaluation.
Evaluation and characterization of solid dispersion
Drut content and percent yield
Physical mixtures and solid dispersions equivalent to 10 mg 
of MET were weighed accurately and dissolved in 25 ml of 
methanol. The solutions were filtered through a membrane 
filter (0.45 mm). The drug content was determined at Journal of Young Pharmacists Vol 3 / No 3  199
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232 nm by UV spectrophotometer (Varian Cary 100) after 
suitable dilution in distilled water (DW). The percentage 
yield of each formulation was also calculated.[18] 
Spectroscopic studies
Drug polymer interactions between MET and compritol 
was studied by the spectral shift method. Ten milligrams of 
drug and solid dispersions equivalent to 10 mg MET were 
dissolved in 25 ml methanol, filtered using Whatman filter 
paper No.41 and degassed by sonication for 30 minutes. After 
appropriate dilutions using DW, the solutions were scanned at 
232 nm with a UV spectrophotometer (Varian Cary 100).[19]
Dissolution study
The dissolution studies[20] were performed using a US 
Pharmacopoeia 24 type II dissolution test apparatus 
(Electrolab TDT-08L, Mumbai, India). The samples 
equivalent to 10 mg MET were placed in a dissolution vessel 
containing 900 ml of double distilled water maintained at 
37 ± 0.5ºC and stirred at 100 rpm. Fivce milliliter samples 
were collected periodically and replaced with a fresh 
dissolution medium. After filtration through Whatman 
filter paper No.41, a concentration of MET was determined 
spectrophotometrically at 232 nm. The data were analyzed 
by PCP Disso software (version 3.0). Solid dispersions were 
optimized based on the percentage drug release criteria 
fixed by USP XXXII[21] as given below:
Release at one hour  : 25 to 40%
Release at two hours : 35 to 55%
Release at six hours  : 65 to 85%
Release at ten hours : Not less than 85%
Dissolution efficiency
The dissolution efficiency (DE)[22] of various solid 
dispersions was calculated. DE is used as the criterion for 
comparing the effect of polymer concentration on the 
release rate. Dissolution efficiency (equation 1) is defined 
as the area under the dissolution curve up to the time, t, 
expressed as a percentage of the area of the rectangle 
described by 100% dissolution in the same time.
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where Y is the percent drug release as the function of 
time, t. T is the total time of drug release and Y100 is 100% 
drug release.
Release experiments
In order to gain insight into the drug release mechanism from 
the solid dispersion, release data[23] of selected formulations 
were examined according to the zero-order, first-order, 
and the Higuchi’s square root of time mathematical 
models, Hixson and Crowell powder dissolution method, 
Korsmeyer and Peppas model, and the release exponent, n, 
was calculated. All the dissolution profiles were subjected 
to model fitting using PCP Disso software (version 3.0).
An n value 0.5 is considered consistent with a diffusion-
controlled release, whereas, a value of 1.0 indicates a 
zero-order release behavior, and intermediate values 
(0.5 > n > 1.0) are defined as anomalous non-fickian 
transport mechanism.[24]
Similarity factor (f2) analysis
In vitro release profile of the marketed metformin-sustained 
release tablets, (Glumet XR®, Cipla) was performed under 
similar conditions as used for in vitro release testing of the 
test product for the release of MET. The similarity factor[25] 
between the two formulations was determined using the 
data obtained from the drug release studies. The data was 
analyzed by the formula shown in equation 2.
f2 = 50 log {[1 + (1/N) Σ (Ri – Ti)2]− 0.5 × 100 }  (2)
where N = number of time points, Ri and Ti = dissolution 
of reference and test products at time i. If f2 is greater 
than 50 it is considered that the two products share similar 
drug release behaviors.[26]
Diffuse reflectance infrared Fourier transform spectroscopy
The diffuse reflectance infrared Fourier transform 
spectroscopy (DRIFTS)[27] spectra of pure metformin, 
physical mixtures, and solid dispersions were obtained, 
after appropriate background subtraction, using an FTIR 
spectrometer (FTIR-640 IR, Varian). About 2 to 3 mg of 
the sample was mixed with dry potassium bromide, and 
the sample was scanned from 4,000 to 400 cm−1.
Differential scanning calorimetry
The calorimeter used was DSC 823e (Mettler Toledo, 
Switzerland), which was equipped with an intracooler and 
a refrigerated cooling system. The Indium standard was 
used to calibrate the DSC temperature and enthalpy scale. 
Nitrogen was used to purge gas through the DSC cell at 
the flow rate of 50 ml/minute and 100 ml/minute through 
the cooling unit. The samples (5 – 10 mg were hermetically 
sealed in an aluminum pan and the heating rate was carried 
out at 5oC/minute.[28]
X-ray powder diffractometry
The powder X-ray diffraction patterns[29] of the powdered 
samples were recorded by using a Philips PW-1729 
X-ray diffractometer. Samples were irradiated with 
monochromatized CuKα radiation and a graphite 200   Journal of Young Pharmacists Vol 3 / No 3
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monochromator. The samples were analyzed in the 5 – 50º 
2θ range at a scan rate of 0.05º per second.
Stability studies
The stability studies[30] were conducted on metformin solid 
dispersions along with the physical mixtures, to assess their 
stability with respect to their physical appearance, drug 
content, and drug release characteristics after storing them 
at 40ºC and relative humidity (RH) of 75% for one month 
and at room temperature, for six months.
RESULTS
Preparation of solid dispersions
Table 1 summarizes the abbreviations, drug content, 
and yield along with dissolution efficiency for the solid 
dispersions. The production yields of solid dispersions 
from solvent evaporation ranged between 91.87 ± 0.55% 
and 97.80 ± 1.99%.
The production yields of solid dispersions from the 
closed melt method ranged between 98.15 ± 1.19% and 
99.20 ± 0.17%. The amount of drug determined in each solid 
dispersion was between 96.70 ± 0.31% and 99.56 ± 1.10% 
for the solvent evaporation method and 96.05 ± 0.64% and 
98.56 ± 0.57% for the closed melt method.
Spectroscopic studies
The UV spectra of MET and solid dispersions were 
studied. There was no shift in the λ max of metformin in 
the presence of compritol.
Dissolution study
The dissolution profiles of metformin solid dispersions, 
along with physical mixtures, in double distilled water, are 
shown in Figures 1 and 2, for solvent evaporation and 
the closed melt method, respectively. MET is a highly 
aqueous soluble and got completely dissolved within a few 
minutes. The dissolution from the physical mixture showed 
approximately the same behavior of pure MET, with only 
a very slight initial slowing down of the drug dissolution 
rate, due to the presence of the hydrophobic polymer, 
which reduced the drug wettability. As the ratio of drug to 
polymer increased there was a significant decrease in the 
drug release from the solid dispersions, reaching 80% of 
dissolved drug after about four and seven hours for SC2 and 
SC3. As the quantity of polymer increased further there was 
Table 1: Abbreviations, drug content, yield, and 
dissolution efficiency for the solid dispersions
Method of 
preparation
Abbreviations % drug 
contenta
% yielda Dissolution 
efficiency
Physical 
mixture 1 : 1
PC1 98.90 ± 0.63 99.15 ± 0.35 -
Physical 
mixture 1 : 2
PC2 97.63 ± 0.51 99.23 ± 0.24 -
Physical 
mixture 1 : 3
PC3 96.72 ± 0.91 99.35 ± 0.34 -
Physical 
mixture 1 : 4
PC4 97.80 ± 1.03 97.83 ± 0.88 -
Physical 
mixture 1 : 5
PC5 98.56 ± 1.08 98.17 ± 1.01 -
Solvent 
evaporation 
1 : 1
SC1 99.56 ± 1.10 97.80 ± 1.99 88.11
Solvent 
evaporation 
1 : 2
SC2 99.0 ± 0.44 96.92 ± 1.48 76.67
Solvent 
evaporation 
1 : 3
SC3 97.0 ± 0.96 97.67 ± 0.94 70.09
Solvent 
evaporation 
1 : 4
SC4 98.90 ± 1.33 91.87 ± 0.55 63.90
Solvent 
evaporation 
1 : 5
SC5 96.70 ± 0.31 92.67 ± 0.81 60.60
Closed melt 
1 : 1
CC1 98.3 ± 1.11 98.20 ± 0.29 91.13
Closed melt 
1 : 2
CC2 98.56 ± 0.57 98.40 ± 1.77 89.68
Closed melt 
1 : 3
CC3 96.40 ± 0.66 99.20 ± 0.17 86.48
Closed melt 
1 : 4
CC4 96.05 ± 0.64 99.10 ± 0.19 87.17
Closed melt 
1 : 5
CC5 96.52 ± 0.85 98.15 ± 1.19 86.28
aexpressed as mean ± (S.D.) standard deviation, n = 3
Figure 1: Dissolution profile of metformin hydrochloride, physical 
mixture, and solid dispersions using the solvent evaporation method
Figure 2: Dissolution profile of metformin hydrochloride, physical 
mixture, and solid dispersions using the closed melt methodJournal of Young Pharmacists Vol 3 / No 3  201
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also a decrease in the amount of drug release from the SD, 
giving a extended release up to 10 hours for SC4 and SC5.
From the dissolution profile of the solid dispersions 
of MET with compritol by the closed melt method, as 
depicted in Figure 2, it is clear that the physical mixture 
shows approximately the same behavior of pure MET 
dissolving completely within a few minutes.
Dissolution efficiency
All the dissolution profiles were subjected to model fitting using 
PCP Disso software (version 3.0). The dissolution efficiency 
(DE) of various solid dispersions was calculated [Table 1].
Dissolution efficiency is used as the criterion for comparing 
the effect of polymer concentration on the release rate. 
The solid dispersions showing the desired release profile 
were selected as optimized batches for further evaluations. 
The solid dispersion of MET with Compritol 888 ATO, 
which was selected as the optimized batch for further 
evaluation was SC4 solid dispersion, depending on the 
release profiles.
Release experiments
Table 2 shows the data for kinetics of solid dispersions. 
The in vitro release pattern of the SC4 SDs was analyzed 
by fitting the dissolution data into various kinetic models. 
It was observed that the R2 value was higher when fitted to 
the Korsmeyer-Peppas equation, as compared to the zero 
order equation, which indicated Peppas as the best fitting 
kinetic model for SC4.
When the data was plotted according to the first order 
equation, the SC4 solid dispersions showed a fair linearity, 
with regression values of 0.9425. When the data was plotted 
according to a Hixson and Crowell’s equation, the SC4 solid 
dispersions did not show much linearity, with a regression 
value of 0.8722. The solid dispersions did not fit into the zero 
order equation, with an R2 value of 0.5832, indicating that 
the dissolution rate of the drug was not independent of the 
amount of drug available for dissolution and diffusion from 
the solid dispersions.
Similarity factor (f2)
The similarity factor f2 method can be used to compare 
two dissolution profiles. The reference drug was used. The 
results of f2 are shown in Table 3.
Similarity factor analysis between the prepared solid 
dispersion and marketed tablet for the release of MET 
showed an f2 factor greater than 50; f2 = 59.55 for SC4 
solid dispersion. The higher the f2 values, the more 
similar the dissolution profiles, so f2 < 50 represented 
non-similar profiles, while f2 > 50 denoted a similarity 
between profiles of prepared solid dispersions and the 
marketed product.
Diffuse reflectance infrared fourier transform spectroscopy
Two typical bands at 3369 cm−1 and 3294 cm−1, relative 
to the N–H primary stretching vibration, and a band at 
3155 cm−1 due to the N–H secondary stretching, and 
characteristic bands at 1626 cm−1 and 1567 cm− 1 assigned to 
C-N stretching are observed in the FTIR spectrum of pure 
MET [Figure 3a]. However, the IR spectra of compritol 
show typical bands at 2820 cm−1, due to C-H stretching, and 
1705 cm−1 due to C = O (carbonyl) stretching [Figure 3g]. 
The physical mixture spectrum [Figure 3f] shows all the 
above bands and can be considered as the sum of drug and 
carrier. The FTIR spectra of the solid dispersions presented 
appreciable shifts and reduction in the intensity of the 
characteristic metformin bands at 3369 cm−1, 3294 cm−1, 
and also at 1626 cm−1, maybe due to the weak hydrogen 
bonding between the drug and polymer.
Table 3: f2 factor results
Time Average % release f2
Reference SC4
0 0.00 0.00 0.00
1 28.30 39.03 55.82
2 41.68 54.93 50.23
3 51.92 60.33 50.99
4 59.17 64.42 52.59
5 64.78 67.41 54.36
6 67.34 71.71 55.50
7 71.17 75.21 56.51
8 75.90 79.24 57.49
9 81.35 82.87 58.56
10 86.81 87.62 59.55
Average - - 59.55
Table 2: Kinetics of optimized solid dispersion of 
metformin hydrochloride
Model  Equation SC4
R2 k
Zero order F = k × t (where F 
is the fraction of 
drug release, k is 
the release constant, 
and t is the time)
0.5832 10.7462
First order Ln F = k × t (where 
F is the fraction of 
drug release, k is 
the release constant, 
and t is the time)
0.9425 –0.2112
Higuchi matrix F = k √ t 0.9607 29.5498
Hixson and Crowell powder 
dissolution method
F = 100  
(1 − (1 − kt)3)
0.8722 –0.0548
Korsmeyer and Peppas modela F = ktn 0.9902 41.0961
a and n (diffusional coefficient) n = 0.3206202   Journal of Young Pharmacists Vol 3 / No 3
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Differential scanning calorimetry
The thermal curves of MET and of selected solid 
dispersion SC4, along with the physical mixture, are shown 
in Figure 4.
The thermal curve of pure MET [Figure 4a] exhibited 
an initial flat profile followed by a sharp endothermic 
effect, with a Tpeak at 231.0°C and an associated 
fusion enthalpy of 292.2 J/g, indicating its anhydrous 
crystalline state. The DSC profile of Compritol 
[Figure 4b] showed a sharp endothermic effect, with a 
Tpeak at 70°C, due to its crystalline nature. The thermal 
curve of the physical mixture [Figure 4c] showed a 
sharp endothermic peak at 68°C, corresponding to 
melting point of COM followed by the flat profile 
and then the reduced endothermic peak of MET at 
233oC. This change in the melting points of both the 
components may be attributed due to the dilution factor. 
The thermal curve of SC4 [Figure 4d] displayed a broad 
endothermic peak ranging from 55ºC to 59ºC followed 
by endothermic and exothermic curves and finally the 
endothermic peak at 231ºC, due to MET.
X-ray powder diffractometry
Figure 5 shows the powder XRD patterns of the pure 
drug, Compritol 888 ATO, physical mixture (1 : 3), and 
solid dispersion prepared by solvent evaporation (SC4) 
with compritol 888 ATO. In powder X-ray diffraction, 
sharper diffraction peaks indicate more crystalline material. 
The sharp, intense representative peaks of pure MET 
[Figure 5a] notably at 2θ angles were 17°, 22°, 23°, 31°, 
and 45°. This series of sharp and intense diffraction 
peaks indicated the crystalline state of pure MET. The 
polymorphic structure of a drug is an important parameter 
that influences the dissolution rate and bioavailability of the 
drug. Compritol shows two peaks [Figure 5b] that occur 
due to lipidic polymorphism at 21° and 23°. The diffraction 
pattern of the physical mixtures [Figure 5c] was simply the 
superimposition of those of the pure components. In case 
of solid dispersion prepared by the solvent evaporation 
method [Figure 5d] the diffraction patterns were very 
similar to those of the physical mixture showing all the 
intense peaks of both the drug and polymer.
Stability studies
No visible changes in the appearance of the solid 
dispersion were observed at the end of the storage 
period. The drug content and dissolution of metformin 
was almost similar to that at time zero during the whole 
period of investigation.
DISCUSSION
It was observed in UV studies that there was slight 
reduction in the absorbance of MET in solid dispersion 
Figure 4: DSC curves of (a) metformin hydrochloride, (b) compritol, 
(c) physical mixture, (d) SC4 SD
Figure 3: FTIR spectra of (a) MET, (b) CC5, (c) CC4, (d) SC5, (e) SC4, 
(f) PC3, and (g) compritolJournal of Young Pharmacists Vol 3 / No 3  203
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than the pure drug. This induced change in absorbance 
was attributed, primarily, to the weak hydrogen bonding.
The in vitro dissolution study showed the slow drug release 
from SD, namely, SC3, SC4, and SC5, which was due to 
an increase in the overall lipophilicity of solid dispersions, 
leading to a decrease in the effective interfacial area between 
the drug and the dissolution medium. This resulted in the 
reduction of the dispersion wettability (the rate of the 
dissolution medium penetration into the solid dispersions) 
and consequently led to a decrease in drug diffusion from 
the dispersions. SC3 showed a sustained release effect with 
92% drug release after 10 hours, but could fit into the release 
criteria as per USP test 2. SC4 solid dispersions followed 
the drug release pattern as per the required conditions and 
was considered as the idle ratio as per USP test 2. Further 
increase in the amount of the polymer resulted in the 
retarded release of the drug with just 82% drug release for 
SC5 after 10 hours, but the required release was not less 
than 85% after 10 hours, hence, ruling out the probability of 
fitting into the release criteria. Initial burst release (more than 
60% in the first hour) from all the solid dispersions prepared 
by the closed melt method could probably be attributed 
to the dissolution of the drug from the surface of the 
dispersions, indicating failure of formation of dispersions. 
None of the solid dispersions showed promising results in 
sustaining the drug release for 10 hours.
The dissolution efficiency values are consistent with the 
dissolution data. For example, the DE value for the SD 
SC1 was 88.11%, whereas, this value decreased to 63.90 
and 60.60% for the SDs SC4 and SC5, respectively, for 
SDs prepared by the solvent evaporation method. The 
DE values were 91.13 and 86.28% for CC1 and CC5, 
respectively. The DE values do not show any major changes 
in case of solid dispersions with compritol using the closed 
melt method.
The kinetic studies when applied to solid dispersion showed 
that the release profile followed was the Korsmeyer-Peppas 
equation. The diffusion mechanism of drug release from 
SC4 was further confirmed by the Korsmeyer-Peppas plots 
that showed fair linearity (R2 > 0.98), with a slope value 
of 0.3206, which was far less than 0.5, suggesting that the 
drug release mechanism from the selected solid dispersions 
was diffusion controlled. From the similarity factor data it 
could be concluded that there was no significant difference 
in the release profile of the prepared solid dispersion and 
the marketed tablets of MET.
In the IR studies there was no sign of any bands, which 
had disappeared, suggesting that the bonding, if present, 
may not have been so strong as to suppress the band. The 
crests and troughs associated with the SC4 SD indicated 
some kind of interaction between the drug and polymer. 
However, the presence of melting peaks in the curve of 
the solid dispersion indicated the absence of drug–carrier 
interactions and/or drug inclusion complexation. The 
DSC and XRD studies proved that there was retention of 
the crystalline nature of the drug in solid dispersion ruling 
out any probability of drug and polymer interaction or 
complex formation.
CONCLUSION
Solid dispersions for the controlled release of MET were 
developed by using compritol. The release rate of MET 
from SD was significantly affected by the preparation 
technique, used for obtaining solid dispersion, and also 
the quantity of polymer in the system. The solvent 
evaporation method was found to be more helpful 
than the closed melt in giving the required sustained 
release action. SD containing 80% Compritol (SC4) 
showed suitable release kinetics, and was free of any 
interaction between the polymers and drug. Drug 
release from SC4 SD followed the Korsmeyer-Peppas 
equation. The FTIR and UV results did not show any 
drug–wax interaction. DSC and PXRD studies ruled out 
the occurrence of solid state interaction and complex 
formation. From the similarity factor data it could be 
concluded that there was no significant difference in the 
release profile of the solid dispersions and the marketed 
tablets of metformin hydrochloride. Therefore, SC4 
SD was selected as the most effective candidate for the 
subsequent development of a well-timed, sustained-
release dosage form of the drug.
Figure 5: XRD patterns of (a) metformin hydrochloride, (b) compritol, 
(c) physical mixtures, (d) SC4 SD204   Journal of Young Pharmacists Vol 3 / No 3
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